drugset / Trial / NCT01770743
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
Phase 2
Completed
168 enrolled
Emergent BioSolutions
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
The purpose of this study is to assess the safety and immunogenicity of an anthrax vaccine. The vaccine schedule and dose will also be assessed.
Timeline
- Start
- 2013-01
- Primary completion
- 2014-02
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BACILLUS ANTHRACIS PROTECTIVE ANTIGEN, ADSORBED | Vaccine | 0.25 ml | Intramuscular |
| Subject | BACILLUS ANTHRACIS PROTECTIVE ANTIGEN, ADSORBED | Vaccine | 0.5 ml | Intramuscular |
| Comparator | BioThrax | Vaccine | 0.5 ml | Intramuscular |